MENU
TRVI
AS OF
Feb 4, 04:39 PM (EDT)
Price
$11.48
Change
-$0.00 (-0.00%)
Capitalization
1.47B
49 days until earnings call
Intraday BUY SELL Signals
+Compare
TRVI
Stock ticker: NASDAQ
AS OF
Feb 4, 04:39 PM (EDT)
Price
$11.48
Change
-$0.00 (-0.00%)
Capitalization
1.47B

TRVI Trevi Therapeutics Forecast, Technical & Fundamental Analysis

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more

TRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for TRVI with price predictions
Feb 03, 2026

Momentum Indicator for TRVI turns positive, indicating new upward trend

TRVI saw its Momentum Indicator move above the 0 level on February 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRVI's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on January 30, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

TRVI moved below its 50-day moving average on January 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TRVI crossed bearishly below the 50-day moving average on January 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TRVI entered a downward trend on February 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.758) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
TRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

TRVI is expected to report earnings to rise 22.00% to -9 cents per share on March 25

Trevi Therapeutics TRVI Stock Earnings Reports
Q4'25
Est.
$-0.10
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.01
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.01
The last earnings report on November 13 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 170.65K shares outstanding, the current market capitalization sits at 1.47B.
A.I. Advisor
published General Information

General Information

a developer and manufacturer of neurological products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCEQX25.030.21
+0.85%
Victory Pioneer Equity Income C
FTSIX42.870.04
+0.09%
FullerThaler Behvrl S-M Cor Eq Instl
PGELX27.71-0.10
-0.36%
George Putnam Balanced R5
LCMMX71.95-1.68
-2.28%
ClearBridge Large Cap Growth O
RPXFX26.52-0.75
-2.75%
RiverPark Large Growth Retail

TRVI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with BIESF. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+4.74%
BIESF - TRVI
48%
Loosely correlated
N/A
PTGX - TRVI
40%
Loosely correlated
+3.06%
NGNE - TRVI
31%
Poorly correlated
-4.20%
DNTH - TRVI
30%
Poorly correlated
-1.35%
MLYS - TRVI
30%
Poorly correlated
+2.24%
More